As of July 2020, American biopharmaceutical company Gilead Sciences expected that they will produce more than two million treatment courses of their antiviral drug remdesivir by the end of the year in order to meet the global real-time need. This statistic depicts the cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020.
Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020
(in 1,000s)
Original manufacturing projections from January to May based on 11-vial treatment course. Projections through end of June based on average 7.78 vials per treatment course. Year-end projection based on average 6.25 vials per treatment course.
Figures reflect the cumulative amount of drug that Gilead expects to produce and are inclusive of supply allocated for clinical trials, compassionate use and expanded access programs, and any potential regulatory authorizations or approvals.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Evaluate Vantage. (July 31, 2020). Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s) [Graph]. In Statista. Retrieved December 30, 2024, from https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
Evaluate Vantage. "Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s)." Chart. July 31, 2020. Statista. Accessed December 30, 2024. https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
Evaluate Vantage. (2020). Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s). Statista. Statista Inc.. Accessed: December 30, 2024. https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
Evaluate Vantage. "Cumulative Amount of Remdesivir Treatment Courses Projected to Be Manufactured by Gilead Sciences during 2020 (in 1,000s)." Statista, Statista Inc., 31 Jul 2020, https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
Evaluate Vantage, Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s) Statista, https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/ (last visited December 30, 2024)
Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s) [Graph], Evaluate Vantage, July 31, 2020. [Online]. Available: https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
